At the time of data analysis, 17 of 23 enrolled patients had received at least two doses of Adcetris and were evaluable for response. All patients had relapsed CD30-positive cutaneous lymphoproliferative disorders, including lymphomatoid papulosis, primary cutaneous anaplastic large cell lymphoma or mycosis fungoides. Patients treated in this trial receive 1.8mg/kg of Adcetris every three weeks for up to a maximum of eight doses. Patients who achieve partial remission or stable disease are eligible to receive an additional eight doses. Eleven of 17 evaluable patients (65%) achieved an objective response, including seven complete remissions and four partial remissions. Six patients had stable disease. These investigator-assessed responses were observed in all three subtypes of CTCL. The clinical trial is ongoing with planned enrollment of 29 patients.
Adcetris is a CD30-directed antibody-drug conjugate already indicated for the treatment of Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates. Adcetris is also indicated for the treatment of systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen.
For more information, call (855) 473-2436 or visit www.seattlegenetics.com.